Craft

Gilead Sciences

Stock Price

$70.8

2024-07-15

Market Capitalization

$88.2 B

2024-07-15

Revenue

$27.1 B

FY, 2023

Gilead Sciences Summary

Company Summary

Overview
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes medicines. Its portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, COVID-19, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.
Type
Public
Status
Active
Founded
1987
HQ
Foster City, CA, US | view all locations
Website
http://www.gilead.com
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key People

  • Daniel O’Day

    Daniel O’Day, Chairman and Chief Executive Officer

    • Andrew Dickinson

      Andrew Dickinson, Chief Financial Officer

    • Flavius Martin

      Flavius Martin, Executive Vice President, Research

    • Jyoti Mehra

      Jyoti Mehra, Executive Vice President, Human Resources

    Operating MetricsView all

    Countries

    35

    FY, 2021

    Products

    21
    5.0%

    FY, 2021

    Phase II Trials Products (Viral Diseases)

    1
    66.7%

    FY, 2021

    LocationsView all

    51 locations detected

    • Foster City, CA HQ

      United States

      333 Lakeside Dr

    • El Segundo, CA

      United States

      2355 Utah Ave

    • Emeryville, CA

      United States

      5858 Horton St #240

    • Miami, FL

      United States

      5200 Blue Lagoon Dr #450

    • Morris Plains, NJ

      United States

      300 The American Rd

    • Oceanside, CA

      United States

      4049 Avenida De La Plata

    and 45 others

    Gilead Sciences Financials

    Summary Financials

    Revenue (Q1, 2024)
    $6.7B
    Gross profit (Q1, 2024)
    $5.1B
    Net income (Q1, 2024)
    ($4.2B)
    Cash (Q1, 2024)
    $4.7B
    EBIT (Q1, 2024)
    ($4.3B)
    Enterprise value
    $109.7B

    Footer menu